What is Dyne Therapeutics, Inc. (DYN) stock price today?

Dyne Therapeutics, Inc. (DYN) is currently trading at $16.64, up 1.65% today.

What is DYN P/E ratio?

Dyne Therapeutics, Inc.'s P/E ratio is -4.84. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DYN return on equity (ROE)?

Dyne Therapeutics, Inc.'s return on equity (ROE) is -64.30%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Dyne Therapeutics, Inc.'s market cap?

Dyne Therapeutics, Inc. has a market capitalization of $3.11B.

NASDAQ · Biotechnology

Dyne Therapeutics, Inc. (DYN) Stock

$16.64 +1.65% NASDAQ: DYN Healthcare

Valuation

Metric	Value
Price	$16.64
Market Cap	$3.11B
P/E Ratio	-4.84
P/B Ratio	3.80
P/S Ratio	0.00
EPS (TTM)	$-3.47
52-Week High	$27.31
52-Week Low	$12.33
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-64.30%
ROA	-52.25%
ROCE	-58.62%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.03
Current Ratio	22.10

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-150.0M	$-171.0M	$-242.0M	$-344.0M	$-468.0M
Net Profit	$-149.0M	$-168.0M	$-236.0M	$-317.0M	$-446.0M
EPS	$-2.93	$-3.23	$-3.95	$-3.37	$-3.47
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$426.0M	$306.0M	$165.0M	$691.0M	$1.2B
Total Liabilities	$57.0M	$54.0M	$74.0M	$61.0M	$215.0M
Cash	$201.0M	$172.0M	$122.0M	$435.0M	$893.0M
Borrowings	$33.0M	$30.0M	$27.0M	$24.0M	$20.0M

Latest News

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? Motley Fool · Jul 4, 2026 Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? Motley Fool · Jul 1, 2026 Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Motley Fool · Jun 26, 2026 Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing MT Newswires · Jun 26, 2026 TD Cowen Initiates Dyne Therapeutics at Buy MT Newswires · Jun 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-120.0M	$-154.0M	$-188.0M	$-292.0M	$-403.0M
Investing Cash Flow	$-142.0M	$84.0M	$83.0M	$-206.0M	$-31.0M
Financing Cash Flow	$1.0M	$1.0M	$2.0M	$37.0M	$0
Net Cash Flow	$-100.0M	$-29.0M	$-51.0M	$313.0M	$458.0M
Free Cash Flow	$-123.0M	$-157.0M	$-189.0M	$-295.0M	$-405.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.34
EV / EBITDA	-4.75
FCF Yield	-16.59%
Quick Ratio	12.02
Interest Coverage	-36.05
Return 1Y	87.02%
Return 3Y	114.19%
Return 5Y	51.59%

Ownership

Insiders Held0.28%

Institutions Held115.65%

Institutions Float Held115.97%

Institutional Holder	Shares	Report Date
T. Rowe Price Investment Management, Inc.	30,785,801	2026-03-31
Janus Henderson Group PLC	13,647,376	2026-03-31
Blackrock Inc.	11,699,870	2026-03-31
Atlas Venture Life Science Advisors, LLC	9,130,465	2026-03-31
FMR, LLC	8,908,980	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (DYN) stock trades at $16.64 with a market capitalization of $3.11B. The stock is valued at a price-to-earnings (P/E) ratio of -4.84, price-to-book of 3.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.33 and $27.31, and currently trades 39.1% below its 52-week high.

On profitability, Dyne Therapeutics, Inc. generates a return on equity (ROE) of -64.30%, return on capital employed of -58.62%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides